Social cognitive performance as a marker of positive psychotic symptoms in young people seeking help for mental health problems

AJ Guastella; DF Hermens; A Van Zwieten; SL Naismith; RSC Lee; C Cacciotti-Saija; EM Scott; IB Hickie

Journal article

Social cognitive performance as a marker of positive psychotic symptoms in young people seeking help for mental health problems

AJ Guastella, DF Hermens, A Van Zwieten, SL Naismith, RSC Lee, C Cacciotti-Saija, EM Scott, IB Hickie

Schizophrenia Research | ELSEVIER | Published : 2013

DOI: 10.1016/j.schres.2013.06.006

Abstract

Previous research has suggested that psychotic symptoms are associated with impairments in social cognition. However, there is limited research evaluating this association in the context of younger patients with a broad range of mental health problems. In the present study, we evaluated social cognitive performance in 115 treatment-seeking participants who presented to a youth mental health service with affective or psychotic disturbances. Participants completed symptom severity measures, a social cognition task (the Reading the Mind in the Eyes Test (RMET)), and a standardised battery of neuropsychological tests. Analyses based on diagnostic groups showed that patients with psychotic illnes..

View full abstract

University of Melbourne Researchers

Rico Lee Author

Related Projects (2)

EMERGING SEVERE MENTAL ILLNESS IN YOUNG PEOPLE

Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still lit..

PREVENTIVE AND EARLY INTERVENTION STRATEGIES IN EMERGING MENTAL DISORDERS IN YOUNG PEOPLE

The Centre will be developed through the extension of a youth psychiatry clinical research program of international standing across Melbourn..

Grants

Awarded by Australian Research Council

Funding Acknowledgements

AJG, DFH, and IBH were supported by an NHMRC Australia Fellowship awarded to IBH (no. 464914). SLN was funded by an NHMRC Clinical Research Fellowship (no. 402864). This research was further supported by an NHMRC Program Grant (no. 350241), an ARC Linkage Grant (LP110100513) and Centres of Clinical Research Excellence Grant (no. 264611). EMS and IBH have received educational and research programs/grants that are supported by the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). All of these funding agencies had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.